Last updated: 2026-10-14 22:33:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Becton, Dickinson and Co. (BDX) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NYSE. The stock is currently priced at $188.93, with a market capitalisation of $51.45B and a P/E ratio of 54.24. Over the past 52 weeks, its price has ranged from $140.11 to $213.08. This page covers its latest market performance, valuation, price trends and company information.
$51.45B | |
$188.26 | |
$287.32 | |
$34.10 | |
$187.37 | |
1.22M | |
1.77M | |
54.24 | |
$213.08 | |
$140.11 | |
2.30% | |
-- |
Becton, Dickinson and Co. (BDX) is trading at $189.47 in after-hours trading as of 2026-10-14 22:29:00, up 1.12% ($2.10) from the regular-session close of $187.37.
After-hours trading shows how investors are pricing BDX after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Becton, Dickinson and Co. (BDX) moved from $180.67 to $188.93, representing a gain of 4.57% ($8.26).
The stock traded between $176.04 and $189.99 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1.59 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 66.9%
BDX is currently trading at $188.93, placing it 66.9% of the way from its 52-week low of $140.11 to its 52-week high of $213.08. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 72000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Becton, Dickinson and Co. (BDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.